Fairchem Organics Ltd
FAIRCHEMORFairchem Organics Ltd's price has outrun its earnings. −10.7% in a year against EPS −73.9% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −10.7% in a year while annual EPS moved −73.9% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a downtrend (95 weeks in) while the P/E sits at the 78th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +900.0% year on year, and 146% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Fairchem Organics Ltd trades at ₹797, in a downtrend and 95 weeks into that stage. That is +17.2% against its own 200-day average. It sits at 96% of a 52-week range of ₹457 to ₹811. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks.
Today the stock is in a downtrend — week 95 of stage 4. At ₹797 it trades +17.2% versus its 200-day average and sits at 96% of its 52-week range (₹457–₹811).
Against the market, two honest reads. Cumulative: over the last 5.6 years the stock moved +23% while the NIFTY 500 moved +104% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 19 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Fairchem Organics Ltd trades at 66.4× P/E, at the pricey end of its own range (78th percentile). Its long-run median P/E is 38.3×, measured across 5.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 66.4× is at the pricey end of its own range (78th percentile), against a long-run median of 38.3× measured over 5.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −73.9% against a −10.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −14.6%/yr price move, ~−24.5%/yr came from earnings growth and ~+9.9 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Fairchem Organics Ltd reads as turning around on its fundamental arc. Turning around — EPS growth swung from −85.6% at the trough to +59.7%, a 2-quarter improving streak, ROCE slipping at 3.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −14.5% | −10.8% | +3.0% | — |
| Profit | −72.7% | −48.5% | −32.2% | — |
| EPS | −73.9% | −49.1% | −33.0% | — |
| Share price | −10.7% | −12.1% | −14.6% | — |
4-Factor Sector Score
44.4/100 — rank 11 of 20 in Chemicals - Organic · 87% evidence confidence
Fairchem Organics Ltd scores 44.4 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 18.4 + 5.7 + 6 + 14.3 = 44.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Fairchem Organics Ltd reported ₹176 Cr of revenue in the Jun 26 quarter, +34.4% year on year. Over 6 years it has compounded at 7.0% a year. The last full year, FY26, came in at ₹460 Cr. The last four reported quarters add to ₹505 Cr.
FY26 revenue came in at ₹460 Cr (−14.5% on the year), capping 6 years at 7.0% compound. The latest quarter (Jun 26) printed ₹176 Cr, +34.4% year on year.
Pace check: the last four quarters averaged −0.2% growth against the decade's 7.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.0% over the last 4 quarters against −10.2%/yr over the last 8 — accelerating; TTM profit +50.0% vs −44.1%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Fairchem Organics Ltd's operating margin is 10.0% in the Jun 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 4.7% to 17.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 10.0%, +6.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 4.7%–17.0%.
Why the margin moved: operating margin went +6.2 pp year on year while gross margin went +5.3 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Fairchem Organics Ltd earned ₹10.0 Cr of net profit in the Jun 26 quarter, +900.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹6.0 Cr. The 6-year compound rate is −25.5%. That is 5.7% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr.
Jun 26 profit was ₹10.0 Cr, +900.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹6.0 Cr (−72.7%), and the 6-year compound rate is −25.5%.
Why profit moved: revenue contributed +34.4% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +256.3% vs revenue −0.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 146% of Fairchem Organics Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹42.0 Cr of operating cash against ₹6.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹30.0 Cr was left as free cash.
FY26: operating cash of ₹42.0 Cr against reported profit of ₹6.0 Cr, leaving free cash of ₹30.0 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 146% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 146%: the cash cycle stretched 48 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Fairchem Organics Ltd's cash conversion cycle runs 139 days in FY26, up from 91 days in FY21. Capital spending ran ₹54.0 Cr over the last 3 years. At FY26 sales of ₹460 Cr each day of that cycle holds about ₹1.3 Cr, so roughly ₹175 Cr sits inside the business at any moment.
FY26: debtors at 54 days, inventory at 96 days — roughly 3.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 139 days, looser than FY21's 91.
The full loop: cash goes out to suppliers and production on day 0; stock waits 96 days to sell; customers pay about 54 days after that; and suppliers themselves are paid at 12 days — netting out to the 139-day cycle.
In money terms: at FY26 sales of ₹460 Cr, each day of the cycle holds about ₹1.3 Cr — so the 139-day loop keeps roughly ₹175 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹54.0 Cr over the last 3 fiscal years against ₹31.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹18.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Fairchem Organics Ltd earns a ROCE of 3% in FY26. Return on invested capital clears the cost of that capital by −9.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.3% net margin on 1.18× asset turns.
FY26 ROCE is 3%.
🚨 Why the return is what it is — the wiring (FY26): 1.3% net margin × 1.18× asset turns × 1.49× balance-sheet leverage ≈ 2.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 2.6% − 12.0% = a −9.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Fairchem Organics Ltd carries total debt of ₹84.0 Cr against shareholder equity of ₹263 Cr as of Mar 26, a debt-to-equity of 0.32. On the annual view that ratio went from 0.27 in FY22 to 0.32 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹84.0 Cr against shareholder equity of ₹263 Cr — a debt-to-equity of 0.32. On the annual view, debt-to-equity went from 0.27 (FY22) to 0.32 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 4.5 points of Fairchem Organics Ltd over 8 quarters, the biggest move on the register. That takes promoters to 63.3% of the company. Domestic institutions moved −2.4 points over the same window, to 2.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +4.5 points over 8 quarters to 63.3%; Domestic institutions: −2.4 points over 8 quarters to 2.8%; Foreign institutions: +0.0 points over 8 quarters to 6.3%.
Why the register moved: promoters drove it (+4.5 points), absorbed on the other side by domestic institutions (−2.4 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Fairchem Organics Ltd: the Z-score reads 6.73. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 6.73 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 6.73.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nitta Gelatin India LtdKERALACHEM | 82.3/100Sector-leading setup78% evidence | 27.8/35 Revenue 11.8% · PAT 34.1% · OPM change 10 pp 83% evidence | 20.2/25 ROCE 31.3% · OPM 28% 76% evidence | 14.3/20 P/E 13.5× · PEG — 50% evidence | 20.0/20 RS sector 71.7% · RS bench 85.7% · 1Y 75.4%4 of 4 weeks ahead to 2026-06-07 100% evidence | |
| Exact sum: 27.8 + 20.2 + 14.3 + 20 = 82.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Balaji Amines LtdBALAMINES | 64.9/100Mixed-positive evidence82% evidence | LEADER | 26.7/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.2/25 ROCE 11% · OPM 25% 76% evidence | 6.6/20 P/E 33.9× · PEG — 50% evidence | 18.4/20 RS sector 27.9% · RS bench 45.8% · 1Y 26.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.2 + 6.6 + 18.4 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3OCCL LtdOCCLLTD | 62.1/100Mixed-positive evidence60% evidence | TURNING | 26.2/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.1/25 ROCE 12.8% · OPM 28% 76% evidence | 11.5/20 P/E 10.9× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 46.7% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 26.2 + 12.1 + 11.5 + 12.3 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Shri Ahimsa Naturals LtdSHRIAHIMSA | 60.8/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 17.8/25 ROCE 21.7% · OPM 28% 95% evidence | 10.3/20 P/E 30.9× · PEG — 15% evidence | 13.8/20 RS sector 22.1% · RS bench 40.5% · 1Y 114.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 17.8 + 10.3 + 13.8 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Indo Amines LtdINDOAMIN | 59.8/100Mixed-positive evidence77% evidence | TURNING | 22.5/35 Revenue 7.6% · PAT 42.9% · OPM change 2 pp 83% evidence | 16.0/25 ROCE 19.9% · OPM 11% 95% evidence | 13.9/20 P/E 11.7× · PEG — 50% evidence | 7.4/20 RS sector -12.9% · RS bench 0.5% · 1Y -15%10 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 16 + 13.9 + 7.4 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Foseco India LtdFOSECOIND | 57.4/100Mixed-positive evidence83% evidence | TURNING | 18.6/35 Revenue 26.9% · PAT 7.5% · OPM change 2 pp 88% evidence | 14.9/25 ROCE 17.4% · OPM 20% 100% evidence | 11.1/20 P/E 39.7× · PEG 1.31 65% evidence | 12.8/20 RS sector 22.8% · RS bench -2.4% · 1Y 5.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.9 + 11.1 + 12.8 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Elantas Beck India LtdELANTAS | 50.5/100Mixed-positive evidence72% evidence | ASLEEP | 17.2/35 Revenue 11.1% · PAT 6.6% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 21.2% · OPM 20% 76% evidence | 7.5/20 P/E 50.9× · PEG — 50% evidence | 7.9/20 RS sector -7.6% · RS bench -2.3% · 1Y -26%1 of 7 weeks ahead 70% evidence |
| Exact sum: 17.2 + 17.9 + 7.5 + 7.9 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Laxmi Organic Industries LtdLXCHEM | 48.2/100Mixed-negative evidence94% evidence | TURNING | 20.8/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.2/25 ROCE 4.7% · OPM 12% 100% evidence | 11.8/20 P/E 39.4× · PEG 1.14 100% evidence | 7.4/20 RS sector -20.5% · RS bench 6.3% · 1Y -13.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 8.2 + 11.8 + 7.4 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Valiant Organics LtdVALIANTORG | 46.9/100Mixed-negative evidence83% evidence | ASLEEP | 23.0/35 Revenue 2.6% · PAT 100% · OPM change 2 pp 83% evidence | 9.6/25 ROCE 5.5% · OPM 12% 95% evidence | 11.4/20 P/E 25.7× · PEG — 50% evidence | 2.9/20 RS sector -18.7% · RS bench -6.3% · 1Y -29.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 9.6 + 11.4 + 2.9 = 46.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -29.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Shree Ganesh Remedies LtdSGRL | 46.6/100Thin evidence · provisional57% evidence | 11.3/35 Revenue -17.3% · PAT -37.7% · OPM change -4.8 pp 53% evidence | 16.4/25 ROCE 19.2% · OPM 31.9% 57% evidence | 8.9/20 P/E 35.1× · PEG — 50% evidence | 10.0/20 RS sector 2.3% · RS bench -9.9% · 1Y -15.8%4 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 11.3 + 16.4 + 8.9 + 10 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Fairchem Organics Ltdthis pageFAIRCHEMOR | 44.4/100Mixed-negative evidence87% evidence | BREAKING OUT | 18.4/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 5.7/25 ROCE 3.3% · OPM 10% 95% evidence | 6.0/20 P/E 66.4× · PEG — 50% evidence | 14.3/20 RS sector 1.2% · RS bench 16.6% · 1Y -12.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 5.7 + 6 + 14.3 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 43.3/100Mixed-negative evidence96% evidence | FADING | 13.8/35 Revenue 4.2% · PAT 1.7% · OPM change 1 pp 88% evidence | 18.0/25 ROCE 21.5% · OPM 21% 100% evidence | 6.0/20 P/E 36.2× · PEG 2.7 100% evidence | 5.5/20 RS sector -10.6% · RS bench 3.4% · 1Y -7.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 18 + 6 + 5.5 = 43.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13GFL LtdGFLLIMITED | 43.0/100Mixed-negative evidence62% evidence | 20.6/35 Revenue 0% · PAT 100% · OPM change 2562 pp 62% evidence | 6.3/25 ROCE 2.1% · OPM 19% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 4.8/20 RS sector -14.7% · RS bench -16.8% · 1Y -28.6%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 6.3 + 11.3 + 4.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14BASF India LtdBASF | 40.7/100Mixed-negative evidence90% evidence | ASLEEP | 11.9/35 Revenue -0.4% · PAT -12.5% · OPM change 1.7 pp 88% evidence | 9.3/25 ROCE 14.5% · OPM 3.2% 100% evidence | 12.2/20 P/E 38.1× · PEG 1.62 100% evidence | 7.3/20 RS sector -4.4% · RS bench -8.7% · 1Y -28%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.3 + 12.2 + 7.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Oriental Aromatics LtdOAL | 38.5/100Mixed-negative evidence74% evidence | TURNING | 13.0/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 7.2/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 231× · PEG — 15% evidence | 9.6/20 RS sector -9.8% · RS bench 15.9% · 1Y -3.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 7.2 + 8.7 + 9.6 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gem Aromatics LtdGEMAROMA | 31.4/100Thin evidence · provisional56% evidence | TURNING | 4.3/35 Revenue -27.3% · PAT -80% · OPM change -8.4 pp 83% evidence | 8.6/25 ROCE 3.4% · OPM 14.2% 95% evidence | 8.5/20 P/E 705× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 4.3 + 8.6 + 8.5 + 10 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sigachi Industries LtdSIGACHI | 25.4/100Adverse evidence77% evidence | TURNING | 6.2/35 Revenue -2.1% · PAT -80% · OPM change -8.8 pp 83% evidence | 6.9/25 ROCE 6.2% · OPM 13.5% 95% evidence | 8.5/20 P/E 30.4× · PEG — 50% evidence | 3.8/20 RS sector -35.5% · RS bench -8.5% · 1Y -33.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 6.9 + 8.5 + 3.8 = 25.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Sacheerome LtdSACHEEROME | 59.9/100Thin evidence · provisional41% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.6/25 ROCE 35.7% · OPM 23% 95% evidence | 10.2/20 P/E 33.3× · PEG — 15% evidence | 11.7/20 RS sector — · RS bench 30.9% · 1Y 141.7%3 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 20.6 + 10.2 + 11.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Jyoti Resins and Adhesives LtdJYOTIRES | 46.1/100Thin evidence · provisional50% evidence | 13.2/35 Revenue 8.7% · PAT -5.5% · OPM change -6 pp 53% evidence | 18.7/25 ROCE 50% · OPM 26% 57% evidence | 10.8/20 P/E 14.3× · PEG — 15% evidence | 3.4/20 RS sector -20.6% · RS bench -30.3% · 1Y -40.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 13.2 + 18.7 + 10.8 + 3.4 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 41.1/100Thin evidence · provisional18% evidence | 14.3/35 Revenue — · PAT -30.4% · OPM change — 18% evidence | 6.8/25 ROCE -2150% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 14.3 + 6.8 + 10 + 10 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Fairchem Organics Ltd's share price today?
Fairchem Organics Ltd trades at ₹797, −10.7% over the past year. The company is valued at ₹1,004 Cr. The stock sits at 96% of its 52-week range of ₹457–₹811, +17.2% versus its 200-day average. On the tape, the price is in a downtrend, 95 weeks in. — as of 31 July 2026.
What were Fairchem Organics Ltd's latest quarterly results?
Fairchem Organics Ltd reported revenue of ₹176 Cr and net profit of ₹10.0 Cr for the Jun 26 quarter. Revenue rose 34.4% and profit rose 900.0% year on year. Earnings per share were ₹7.95. The operating margin was 10.0%, 6.0 pp higher than a year earlier. — as of 31 July 2026.
What is Fairchem Organics Ltd's revenue?
Fairchem Organics Ltd reported revenue of ₹176 Cr in the Jun 26 quarter, +34.4% year on year. For the full FY26 fiscal year, revenue was ₹460 Cr (−14.5%). Over the last 6 years revenue compounded at 7.0% a year. — as of 31 July 2026.
What is Fairchem Organics Ltd's profit?
Fairchem Organics Ltd earned ₹10.0 Cr of net profit in the Jun 26 quarter, +900.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹6.0 Cr. The operating margin ran 10.0% in the latest quarter. — as of 31 July 2026.
What is Fairchem Organics Ltd's market cap?
Fairchem Organics Ltd's market capitalisation is ₹1,004 Cr at a share price of ₹797. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Fairchem Organics Ltd's P/E ratio?
Fairchem Organics Ltd trades at a P/E of 66.4×, at the 78th percentile of its own 5-year range, against a long-run median of 38.3×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Fairchem Organics Ltd pay a dividend?
Not in its latest year — Fairchem Organics Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 5 of its last 7 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Fairchem Organics Ltd overvalued?
On its own history, Fairchem Organics Ltd looks expensive against its own history: its P/E of 66.4× sits at the 78th percentile of its 5-year range (long-run median 38.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Fairchem Organics Ltd growing?
Yes — Fairchem Organics Ltd is growing: latest-quarter revenue +34.4% year on year, profit +900.0%, and the margin +6.0 pp at 10.0%. The 6-year compound rates are 7.0% (revenue) and −25.5% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Fairchem Organics Ltd performing?
Fairchem Organics Ltd is in a downtrend, 95 weeks in. Its latest quarter's revenue rose 34.4% and profit rose 900.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 19 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Fairchem Organics Ltd in?
Turning around — EPS growth swung from −85.6% at the trough to +59.7%, a 2-quarter improving streak, ROCE slipping at 3.0%. The read comes from the last 12 quarters of growth (revenue growth +0.0% latest, profit growth +50.0% latest, eps growth +59.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Fairchem Organics Ltd in an uptrend?
No — the price is in a downtrend (week 95 of stage 4), trading +17.2% versus its 200-day average and at 96% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Fairchem Organics Ltd beating the market?
On recent form, yes — Fairchem Organics Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.6 years the stock moved +23% against the NIFTY 500's +104% — behind the index over the full window. — as of 31 July 2026.
Will Fairchem Organics Ltd's share price go up?
This page publishes no price forecast for Fairchem Organics Ltd. What it measures instead: the share price is ₹797, the price is in a downtrend 95 weeks in. Its P/E of 66.4× sits at the 78th percentile of its own 5-year range. — as of 31 July 2026.
Who owns Fairchem Organics Ltd?
Promoters hold 63.3% of Fairchem Organics Ltd, foreign institutions 6.3%, domestic institutions 2.8% and the public 27.6% (latest quarter). The biggest move on the register over the last two years: Promoters added 4.5 points over 8 quarters. — as of 31 July 2026.
Does Fairchem Organics Ltd have too much debt?
It is moderate — Fairchem Organics Ltd's debt-to-equity is 0.32, and operating profit covers the interest bill 6×. FY26 borrowings were ₹84.0 Cr against equity of ₹263 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Fairchem Organics Ltd's capex?
Fairchem Organics Ltd spent ₹54.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹18.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Fairchem Organics Ltd's cash flow?
Fairchem Organics Ltd generated ₹42.0 Cr of operating cash flow in FY26 and ₹30.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹6.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Fairchem Organics Ltd's profit real cash?
Yes — over the last 3 fiscal years, 146% of Fairchem Organics Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹42.0 Cr against reported profit of ₹6.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
How financially safe is Fairchem Organics Ltd?
On the balance sheet, the Z-score reads 6.73 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 31 July 2026.
Where is Fairchem Organics Ltd in its business cycle?
Fairchem Organics Ltd's FY26 operating margin was 4.7%, against a 7-year band of 4.7%–17.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 10.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Fairchem Organics Ltd story?
The sharpest disagreement: the price moved −10.7% in a year while annual EPS moved −73.9% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Fairchem Organics Ltd a stock worth studying right now?
This is not investment advice. The machine read: Fairchem Organics Ltd's price has outrun its earnings. −10.7% in a year against EPS −73.9% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.